Novo Nordisk A/S (NYSE:NVO)’s stock price hit a new 52-week high during mid-day trading on Friday . The company traded as high as $57.41 and last traded at $57.35, with a volume of 489113 shares traded. The stock had previously closed at $56.37.

NVO has been the subject of a number of recent research reports. Jefferies Financial Group cut shares of Novo Nordisk A/S from a “hold” rating to an “underperform” rating in a report on Friday, August 30th. Citigroup upgraded shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Tuesday, September 17th. Zacks Investment Research upgraded shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating and set a $50.00 price objective for the company in a report on Monday, July 15th. ValuEngine upgraded shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a report on Friday, November 1st. Finally, Pareto Securities upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Monday, August 5th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and six have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $159.65.

The stock has a market cap of $135.11 billion, a price-to-earnings ratio of 22.96, a price-to-earnings-growth ratio of 2.28 and a beta of 0.61. The company has a debt-to-equity ratio of 0.06, a quick ratio of 0.73 and a current ratio of 1.00. The stock’s 50-day simple moving average is $53.15 and its two-hundred day simple moving average is $50.60.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Friday, November 1st. The company reported $0.64 EPS for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.02. The business had revenue of $4.51 billion during the quarter, compared to analyst estimates of $4.55 billion. Novo Nordisk A/S had a net margin of 32.44% and a return on equity of 75.48%. As a group, research analysts predict that Novo Nordisk A/S will post 2.45 earnings per share for the current year.

A number of large investors have recently bought and sold shares of the stock. Advisors Preferred LLC bought a new stake in Novo Nordisk A/S during the second quarter worth about $26,000. Prime Capital Investment Advisors LLC bought a new stake in Novo Nordisk A/S during the third quarter worth about $28,000. Winthrop Partners WNY LLC bought a new stake in Novo Nordisk A/S during the third quarter worth about $28,000. Valeo Financial Advisors LLC grew its stake in Novo Nordisk A/S by 510.7% during the second quarter. Valeo Financial Advisors LLC now owns 629 shares of the company’s stock worth $32,000 after buying an additional 526 shares during the last quarter. Finally, Wealthcare Advisory Partners LLC grew its stake in Novo Nordisk A/S by 75.6% during the second quarter. Wealthcare Advisory Partners LLC now owns 864 shares of the company’s stock worth $44,000 after buying an additional 372 shares during the last quarter. 7.36% of the stock is owned by hedge funds and other institutional investors.

About Novo Nordisk A/S (NYSE:NVO)

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Recommended Story: What is Cost of Debt?

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.